Sectors
MNPR
Monopar Therapeutics Inc.
111.93
1 x 113.21
1 x 111.95
bid
ask
+
0.04
0.04%
1 @ 07:30 PM
111.50 -0.43 (0.38%)
| Ytd | 71.41% | |
| 1y | 227.76% |
106.75
day range
112.97
32.77
52 week range
124.82
| Open | 110.70 | Prev Close | 111.89 | Low | 106.75 | High | 112.97 | Mkt Cap | 751.29M |
| Vol | 141.85K | Avg Vol | 218.61K | EPS | -2.20 | P/E | N/A | Forward P/E | -10.17 |
| Beta | 1.10 | Short Ratio | 0.15 | Inst. Own | 24.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 105.83 | 200-d Avg | 74.24 | 1yr Est | 27.33 |
| Income Statement | |||
| Operating Expenses | 6.64M | ||
| Research and Development Expense | 4.77M | ||
| Selling, General and Administrative Expense | 1.88M | ||
| Operating Income | -6.64M | ||
| Net Income | -5.31M | ||
| Net Income Common Stock | -5.31M | ||
| Net Income Common Stock (USD) | -5.31M | ||
| Consolidated Income | -5.31M | ||
| Earnings per Basic Share | -0.62 | ||
| Earnings per Basic Share (USD) | -0.62 | ||
| Earnings per Diluted Share | -0.62 | ||
| Earning Before Interest & Taxes (EBIT) | -5.31M | ||
| Earning Before Interest & Taxes (USD) | -5.31M | ||
| Weighted Average Shares | 8.54M | ||
| Weighted Average Shares Diluted | 8.54M | ||
| Balance Sheet | |||
| Cash and Equivalents | 52.76M | ||
| Cash and Equivalents (USD) | 52.76M | ||
| Investments | 81.54M | ||
| Investments Current | 81.54M | ||
| Current Assets | 134.76M | ||
| Property, Plant & Equipment Net | 215.12K | ||
| Total Assets | 134.98M | ||
| Total Debt | 107.83K | ||
| Current Liabilities | 4.02M | ||
| Debt Non-Current | 107.83K | ||
| Total Liabilities | 4.12M | ||
| Accumulated Retained Earnings (Deficit) | -98.72M | ||
| Accumulated Other Comprehensive Income | 91.32K | ||
| Shareholders Equity | 130.85M | ||
| Shareholders Equity (USD) | 130.85M | ||
| Assets Non-Current | 215.12K | ||
| Total Debt (USD) | 107.83K | ||
| Liabilities Non-Current | 107.83K | ||
| Trade and Non-Trade Payables | 4.02M | ||
| Cash Flow | |||
| Net Cash Flow from Financing | -647.39K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 213.50K | ||
| Issuance (Purchase) of Equity Shares | 7.58K | ||
| Net Cash Flow from Investing | 4.12M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 4.12M | ||
| Net Cash Flow from Operations | -3.25M | ||
| Effect of Exchange Rate Changes on Cash | -7.14K | ||
| Share Based Compensation | 1.43M | ||